Page 86 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Chapter 4
84
Table 1. Main features of studies included in the review
Study
Baseline pathology
No. of cases
Specimen
Follow-up term
Follow-up HPV measure tested?
Distinction polyploidy/ gain
No. of evaluated cells
Cutoff
Cases with gain
Disease outcome
Heselmayer- Haddad, 2005
German PAP3D cytology (resembling CINa 1/2)
22
Liquid- based cytology
2m – 2y
Cytology No
Yes
Different for each case: based on cell density and focused on aberrant cells
> 2 signals in > 20% of cells (pragmatic)
Gain: 7/22 (32%)
Remission: 10/22 (45%) Progression: 12/22 (55%)
Alameda, 2009
LSILb cytology
30*
Liquid- based cytology
6, 12 and 24m
Cytology Yes followed by colposcopy with
No
Min 400
> 2 signals
in > 1.6% of cells (based on mean gain in control population)
19/30 (63%)
Remission:
6m: 13/30 (43%) 12m: 18/26 (69%) 24: 13/21 (62%)
Jalali, 2010
LSIL cytology
47
Liquid - based cytology
< 12m – 85m
Cytology No (n=16) or biopsy
(n=31)
Yes, tetraploidy ruled out by defining gain as >4 signals
15-20 HPF
>4 signals in ≥ 2 cells, pragmatic
17/47 (36%)
Non-progression: 36/47 (77%) Progression: 11/47 (23%)
Lan, 2012
CIN 1-2, histological diagnosis
54
Liquid- based cytology
24 m
Colposcopy Yes with biopsy
No
Min 100
> 2 signals in
> 5.48% of cells (based on mean gain + 3SD of control population)
27/54 (50%)
Regression: 20/54 (37%) Persistence: 21/54 (39%) Progression: 13/54 (24%)
biopsy on indication
Persistence/ progression : 6m: 17/30 (57%) 12m: 8/26 (31%) 24m: 8/21 (38%)
Gain/ tetraploidy: 15/22 (68%)
table continues